Whereas, a phase I / II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma
multiforme led to no significant improvement in overall survival, which could be due to inconsistent autophagy inhibition in patients treated with this regimen [29].
Not exact matches
A CAT scan and an MRI
lead to a diagnosis more daunting than the first: glioblastoma
multiforme, grade 4.
The results suggest the simultaneous activation of certain molecular pathways — actions among molecules in a cell that can
lead to change — in particular the MAPK and PI3K cellular pathways, triggered tumor initiation and produced increasingly dense low - grade gliomas that quickly progressed to glioblastoma
multiforme (GBM).
These preclinical studies have
led to a clinical trial for patients with glioblastoma
multiforme (www.clinicaltrials.gov NCT02046187).
Background ImmunoCellular Therapeutics is a California - based oncology firm with the
lead candidate ICT - 107 entering Phase II for patients with a particular form of brain cancer, glioblastoma
multiforme (GBM).